Citations

Clear

21 citation(s) found for "Mason, Andrew".

In-season assessment of dietary intake and match demands of male collegiate rugby sevens players
Horlock, Conor, Allen, Leah, Jones, Margaret T., Jagim, Andrew R., Fields, Jennifer B., Horlock, Conor, Allen, Leah, Jones, Margaret T., Jagim, Andrew R., Fields, Jennifer B.

Mayo Clinic

Journal of the International Society of Sports Nutrition | December 18, 2025 | Volume: 22 | Issue: sup2 | Pages: No page available

10.1080/15502783.2025.2550172 Get It

Technical Factors Associated With the Benefit of Prophylactic Pancreatic Stent Placement During High-Risk Endoscopic Retrograde Cholangiopancreatography: A Secondary Analysis of the SVI Trial Data Set
Elmunzer, B. Joseph , Zhang, Jingwen , Coté, Gregory A. , Wani, Sachin , Shah, Raj J. , Bang, Ji Young , Varadarajulu, Shyam , Singh, Vikesh K. , Khashab, Mouen A. , Kwon, Richard S. , Scheiman, James M., Keilin, Steven , Chak, Amitabh , Slivka, Adam, Mullady, Daniel , Kushnir, Vladimir , Buxbaum, James , Keswani, Rajesh N. , Gardner, Timothy B. , Forbes, Nauzer , Rastogi, Amit, Ross, Andrew S., Law, Joanna K. , Chen, Yen‐I , Smith, Zachary L. , Petersen, Bret T. , Wang, Andrew Y. , Saltzman, John R. , Spitzer, Rebecca L., Ordiah, Collins, Spino, Cathie , Foster, Lydia D. , Durkalski‐Mauldin, Valerie, Group*, on behalf of the SVI Study, Shah, Raj , Singh, Vikesh K , Kwon, Richard S , Willingham, Field F , Chak, Amitabh , Mullady, Daniel , Forbes, Nauzer , Ross, Andrew , Law, Joanna , Chen, Yen-I , Smith, Zachary L , Serrano, Jose , Petersen, Bret, Wang, Andrew Y , Saltzman, John R , Spino, Cathie , Foster, Lydia D , Edmundowicz, Steven A. , Willingham, Field F. , Papachristou, Georgios I. , Yachimski, Patrick , Barkun, Alan , Serrano, José , Group*, on behalf of the SVI Study

Mayo Clinic

American Journal of Gastroenterology | August 27, 2024 | Volume: 120 | Issue: 4 | Pages: 811-815

10.14309/ajg.0000000000003052 | PMID 39207308 Get It

INTRODUCTION: Prophylactic pancreatic stent placement (PSP) is effective for preventing pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP) in high-risk cases, but the optimal technical approach to this intervention remains uncertain. METHODS: In this secondary analysis of 787 clinical trial patients who underwent successful stent placement, we studied the impact of (i) whether pancreatic wire access was achieved for the sole purpose of PSP or naturally during the conduct of the case, (ii) the amount of effort expended on PSP, (iii) stent length, (iv) stent diameter, and (v) guidewire caliber. We used logistic regression models to examine the adjusted association between each technical factor and post-ERCP pancreatitis (PEP). RESULTS: Ninety-one of the 787 patients experienced PEP. There was no clear association between PEP and whether pancreatic wire access was achieved for the sole purpose of PSP (vs occurring naturally; odds ratio [OR] 0.82, 95% confidence interval [CI] 0.37–1.84), whether substantial effort expended on stent placement (vs nonsubstantial effort; OR 1.58, 95% CI 0.73–3.45), stent length (>5 vs ≤5 cm; OR 1.01, 95% CI 0.63–1.61), stent diameter (≥5 vs <5 Fr; OR 1.13, 95% CI 0.65–1.96), or guidewire caliber (0.035 vs 0.025 in; 0.83, 95% CI 0.49–1.41). DISCUSSION: The 5 modifiable technical factors studied in this secondary analysis of large-scale randomized trial data did not appear to have a strong impact on the benefit of prophylactic PSP in preventing PEP after high-risk ERCP. Within the limitations of post hoc subgroup analysis, these findings may have important implications in procedural decision making and suggest that the benefit of PSP is robust to variations in technical approach.
Global prospective case series of ERCPs using a single-use duodenoscope
Bruno, Marco J. , Beyna, Torsten , Carr‐Locke, David L. , Chahal, Prabhleen , Costamagna, Guido , Devereaux, Benedict , Giovannini, Marc, Khor, Christopher , Lau, James Y., May, Gary R. , Muthusamy, V. Raman , Petersen, Bret T. , Raijman, Isaac , Reddy, D. Nageshwar , Ross, Andrew S., Sejpal, Divyesh V., Sherman, Stuart , Siddiqui, Uzma D. , Ziady, Christopher, Peetermans, Joyce , Rousseau, Matthew , Slivka, Adam, Group, EXALT Single-use Duodenoscope Study, Fichera, Alessandro , Pleskow, Douglas , Goenka, Mahesh Kumar , Patel, Sandeep , Petersen, Bret T. , Pleskow, Douglas K. , Repici, Alessandro , Group, EXALT Single-use Duodenoscope Study

Mayo Clinic

Endoscopy | July 18, 2023 | Volume: 55 | Issue: 12 | Pages: 1103-1114

10.1055/a-2131-7180 | PMID 37463599 Get It

Background The first commercialized single-use duodenoscope was cleared by the US Food and Drug Administration in December 2019. Data regarding endoscopic retrograde cholangiopancreatography (ERCP) using a single-use duodenoscope are needed on a broader range of cases conducted by endoscopists with varying levels of experience in a wide range of geographic areas. Methods 61 endoscopists at 22 academic centers in 11 countries performed ERCP procedures in adult patients aged ≥ 18. Outcomes included ERCP completion for the intended indication, rate of crossover to a reusable endoscope, device performance ratings, and serious adverse events (SAEs). Results Among 551 patients, 236 (42.8 %) were aged > 65, 281 (51.0 %) were men, and 256 (46.5 %) had their procedure as an inpatient. ERCPs included 196 (35.6 %) with American Society for Gastrointestinal Endoscopy complexity of grades 3–4. A total of 529 ERCPs (96.0 %) were completed: 503 (91.3 %) using only the single-use duodenoscope, and 26 (4.7 %) with crossover to a reusable endoscope. There were 22 ERCPs (4.0 %) that were not completed, of which 11 (2.0 %) included a crossover and 11 (2.0 %) were aborted cases (no crossover). Median ERCP completion time was 24.0 minutes. Median overall satisfaction with the single-use duodenoscope was 8.0 (scale of 1 to 10 [best]). SAEs were reported in 43 patients (7.8 %), including 17 (3.1 %) who developed post-ERCP pancreatitis. Conclusions In academic medical centers over a wide geographic distribution, endoscopists with varying levels of experience using the first marketed single-use duodenoscope had good ERCP procedural success and reported high performance ratings for this device.
Ursodeoxycholic Acid Treatment–Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis
Veer, Rozanne C. de , Hooff, Maria C. van , Thorburn, Douglas , Janssen, Harry L.A. , Nevens, Frederik , Lindor, Keith D. , Floreani, Annarosa , Ponsioen, Cyriel Y. , Mayo, Marlyn J. , Mason, Andrew L. , Goet, Jorn , Bruns, Tony , Verhelst, Xavier , Meer, Adriaan J. van der, Group, on behalf of the Global PBC Study, Bruns, Tony , Mason, Andrew , Verhelst, Xavier , Corpechot, Christophe , Invernizzi, Pietro , Lammers, Willem J. , Battezzati, Pier Maria , Parés, Albert , Kowdley, Kris V. , Trivedi, Palak Jitendrakumar , Hirschfield, Gideon M. , Dalekos, George Ν. , Gatselis, Nikolaos , Hansen, Bettina E. , Harms, Maren H. , Meer, Adriaan J. van der, Group, on behalf of the Global PBC Study

Mayo Clinic

American Journal of Gastroenterology | January 9, 2023 | Volume: 118 | Issue: 7 | Pages: 1196-1203

10.14309/ajg.0000000000002128 | PMID 36621963 Get It

INTRODUCTION: Treatment of primary biliary cholangitis (PBC) can improve the GLOBE score. We aimed to assess the association between changes in the GLOBE score (ΔGLOBE) and liver transplantation (LT)–free survival in patients with PBC who were treated with ursodeoxycholic acid (UDCA). METHODS: Among UDCA-treated patients within the Global PBC cohort, the association between ΔGLOBE (ΔGLOBE 0–1 : during the first year of UDCA, ΔGLOBE 1–2 : during the second year) and the risk of LT or death was assessed through Cox regression analyses. RESULTS: Overall, 3,775 UDCA-treated patients were included; 3,424 (90.7%) were female, the median age was 54.0 (interquartile range [IQR] 45.9–62.4) years, and the median baseline GLOBE score was 0.25 (IQR −0.47 to 0.96). During a median follow-up of 7.2 (IQR 3.7–11.5) years, 730 patients reached the combined end point of LT or death. The median ΔGLOBE 0–1 was −0.27 (IQR −0.56 to 0.02). Cox regression analyses, adjusted for pretreatment GLOBE score and ΔGLOBE 0–1 2 , showed that ΔGLOBE was associated with LT or death (adjusted hazard ratio 2.28, 95% confidence interval 1.81–2.87, P < 0.001). The interaction between baseline GLOBE score and ΔGLOBE 0–1 was not statistically significant ( P = 0.296). The ΔGLOBE 1–2 was associated with LT or death (adjusted hazard ratio 2.19, 95% confidence interval 1.67–2.86, P < 0.001), independently from the baseline GLOBE score and the change in GLOBE score during the first year of UDCA. DISCUSSION: UDCA-induced changes in the GLOBE score were significantly associated with LT-free survival in patients with PBC. While the relative risk reduction of LT or death was stable, the absolute risk reduction was heavily dependent on the baseline prognosis of the patient.
Liver transplant‐free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid
Veer, Rozanne C. de , Harms, Maren H. , Thorburn, Douglas , Janssen, Harry L.A. , Nevens, Frederik , Lindor, Keith D. , Floreani, Annarosa , Ponsioen, Cyriel Y. , Mayo, Marlyn J. , Parés, Albert , Mason, Andrew L. , Bruns, Tony , Buuren, Henk R. van , Meer, Adriaan J. van der, Group, the Global PBC Study, van der Meer, Adriaan J , Invernizzi, Pietro , Lindor, K D , Mayo, Marlyn J , Mason, Andrew , Hirschfield, Gideon M , Bruns, Tony , Verhelst, Xavier , Corpechot, Christophe , Invernizzi, Pietro , Battezzati, Pier Maria , Kowdley, Kris V. , Trivedi, Palak Jitendrakumar , Hirschfield, Gideon M. , Dalekos, George Ν. , Gatselis, Nikolaos , Verhelst, Xavier , Lammers, Willem J. , Hansen, Bettina E. , Meer, Adriaan J. van der, Group, the Global PBC Study

Mayo Clinic

Alimentary Pharmacology & Therapeutics | September 23, 2022 | Volume: 56 | Issue: 9 | Pages: 1408-1418

10.1111/apt.17226 | PMID 36138566 Get It

SummaryBackgroundAfter 1 year of ursodeoxycholic acid (UDCA), patients with primary biliary cholangitis (PBC) may have a normal GLOBE score despite high alkaline phosphatase (ALP) levels.AimTo assess the association between ALP and liver transplantation (LT)‐free survival according to the GLOBE scoreMethodsAmong patients with a normal or elevated GLOBE score in the Global PBC cohort, the association between ALP after 1 year of UDCA and the risk of LT/death was assessed. The LT‐free survival was compared with that of a matched general population.ResultsAfter 1 year of UDCA, ALP was associated with the risk of LT/death (aHR 1.31, 95% CI 1.003–1.72, p = 0.048) among 2729 patients with a normal GLOBE score. The 10‐year LT‐free survival among these patients with an ALP >2.0 × ULN was 94.0% (95% CI 90.1–97.9) for those <50 years, and 82.6% (95% CI 76.5–88.7) for those ≥50 years, which was significantly lower (p = 0.040) and similar (p = 0.736) to that of the matched population, respectively. The 10‐year LT‐free survival in patients ≥50 years with normal GLOBE score and normal ALP (90.8%, 95% CI 87.7–93.9) was significantly higher (p = 0.022) than the matched population. Among 1045 patients with an elevated GLOBE score, ALP was associated with LT/death only in those <50 years (aHR 1.38, 95% CI 1.06–1.81, p = 0.016).ConclusionThe LT‐free survival of patients with PBC with a normal GLOBE score is optimal in case of normal ALP levels, also in relation to the general population. Despite their generally favourable prognosis, an elevated ALP level may still indicate a need for add‐on therapy.
P09 Long-term obeticholic acid (OCA) for Primary Biliary Cholangitis (PBC) in a clinical trial improved event free survival (death, liver transplant and hepatic decompensation) compared to external controls from the GLOBAL PBC real-world database
Perez, Carla , Adekunle, Femi, Mayne, Tracy J. , Malecha, Elizabeth Smoot, Ness, Eric , Meer, Adriaan J Van Der, Nevens, Frederik , Bruns, Tony , Floreani, Annarosa , Mayo, Marlyn J. , Thorburn, Douglas , Gulamhusein, Aliya , Bowlus, Christopher L. , Lindor, Keith D. , Bruns, Tony , Bowlus, Christopher L , Meer, Adriaan van der , Lammers, Willem J. , Trivedi, Palak Jitendrakumar , Battezzati, Pier Maria , Kowdley, Kris V. , Cazzagon, Nora , Mason, Andrew L. , Parés, Albert , Londoño, Maria, Invernizzi, Pietro , Carbone, Marco , Lleò, Ana , Dalekos, George Ν. , Gatselis, Nikolaos , Verhelst, Xavier , Janssen, Harry L.A. , Trauner, Michael , Corpechot, Christophe , Hirschfield, Gideon M. , Hansen, Bettina E.

Mayo Clinic

Abstracts | September 20, 2022 | Volume: No volume available | Issue: No issue available | Pages: A37-A37

10.1136/gutjnl-2022-basl.60 Get It

Outcomes of peroral endoscopic myotomy in patients with achalasia and prior bariatric surgery: A multicenter experience
Bomman, Shivanand , Klair, Jagpal S. , Ashat, Munish , Keech, John , Parekh, Kalpaj R. , Nau, Peter , Hanada, Yuriko, Song, Lei , Kozarek, Richard A. , Irani, Shayan , Ross, Andrew S., Krishnamoorthi, Rajesh , Abiad, Rami G. El , Gerke, Henning , Song, L M Wong Kee, Low, Donald E.

Mayo Clinic

Diseases of the Esophagus | June 29, 2021 | Volume: 34 | Issue: 12 | Pages: No page available

10.1093/dote/doab044 | PMID 34184036 Get It

Summary Peroral endoscopic myotomy (POEM) in patients with achalasia who are status post bariatric surgery may be technically challenging due to postsurgical scarring and altered anatomy. The aim of the study was to assess the efficacy and safety of POEM for achalasia in patients with prior bariatric surgery. A review of prospectively maintained databases at three tertiary referral centers from January 2015 to January 2021 was performed. The primary outcome of interest was clinical success, defined as a post-treatment Eckardt score ≤ 3 or improvement in Eckardt score by ≥ 1 when the baseline score was &lt;3, and improvement of symptoms. Secondary outcomes were adverse event rates and symptom recurrence. Sixteen patients status post Roux-en-Y gastric bypass (n = 14) and sleeve gastrectomy (n = 2) met inclusion criteria. Indications for POEM were achalasia type I (n = 2), type II (n = 9), and type III (n = 5). POEM was performed either by anterior or posterior approach. The pre-POEM mean integrated relaxation pressure was 26.2 ± 7.6 mm Hg. The mean total myotomy length was 10.2 ± 2.7 cm. The mean length of hospitalization was 1.4 ± 0.7 days. Pre- and postprocedure Eckardt scores were 6.1 ± 2.1 and 1.7 ± 1.8, respectively. The overall clinical success rate was 93.8% (15/16) with mean follow-up duration of 15.5 months. One patient had esophageal leak on postprocedure esophagram and managed endoscopically. Dysphagia recurred in two patients, which was successfully managed with pneumatic dilation with or without botulinum toxin injection. POEM appears to be safe and effective in the management of patients with achalasia who have undergone prior bariatric surgery.
Single Topic Conference on Autoimmune Liver Disease from the Canadian Association for the Study of the Liver
Allegretti, Jessica R. , Cheung, Angela , Jones, David , Kerkar, Nanda , Rizvi, Sumera, Bai, Wayne, Gilmour, Susan , Gulamhusein, Aliya , Guttman, Orlee R. , Onófrio, Fernanda de Quadros , Santamaría, Pere , Stueck, Ashley , Swain, Mark G. , Vincent, Catherine , Ricciuto, Amanda , Ricciuto, Amanda , Montaño‐Loza, Aldo J. , Ebadi, Maryam , Levy, Cynthia , Vierling, John Moore , Álvarez, Fernando , Hansen, Bettina E. , MacParland, Sonya A. , Mason, Andrew L. , Hirschfield, Gideon M.

Mayo Clinic

Canadian Liver Journal | June 10, 2021 | Volume: 4 | Issue: 4 | Pages: 401-425

10.3138/canlivj-2021-0006 | PMID 35989897 Get It

Autoimmune liver disease (AILD) spans a spectrum of chronic disorders affecting the liver parenchyma and biliary system. Three main categories of AILD are autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC). This review condenses the presentation and discussions of the Single Topic Conference (STC) on AILD that was held in Ottawa, Ontario, in November 2019. We cover generalities regarding disease presentation and clinical diagnosis; mechanistic themes; treatment paradigms; clinical trials, including approaches and challenges to new therapies; and looking beyond traditional disease boundaries. Although these diseases are considered autoimmune, the etiology and role of environmental triggers are poorly understood. AILDs are progressive and chronic conditions that affect survival and quality of life. Advances have been made in PBC treatment because second-line treatments are now available (obeticholic acid, bezafibrate); however, a significant proportion still present suboptimal response. AIH treatment has remained unchanged for several decades, and data suggest that fewer than 50% of patients achieve a complete response and as many as 80% develop treatment-related side effects. B-cell depletion therapy to treat AIH is in an early stage of development and has shown promising results. An effective treatment for PSC is urgently needed. Liver transplant remains the best option for patients who develop decompensated cirrhosis or hepatocellular carcinoma within specific criteria, but recurrent AILD might occur. Continued efforts are warranted to develop networks for AILD aimed at assessing geo-epidemiological, clinical, and biochemical differences to capture the new treatment era in Canada.
Effectiveness and Safety of EUS Rendezvous After Failed Biliary Cannulation With ERCP
Klair, Jagpal S. , Zafar, Yousaf , Ashat, Munish , Bomman, Shivanand , Jayaraj, Mahendran , Law, Joanna K. , Larsen, Michael , Singh, Dhruv P. , Rustagi, Tarun , Irani, Shayan , Ross, Andrew , Kozarek, Richard A. , Krishnamoorthi, Rajesh , Murali, Arvind R.

Mayo Clinic

Journal of Clinical Gastroenterology | April 9, 2021 | Volume: 57 | Issue: 2 | Pages: 211-217

10.1097/mcg.0000000000001543 | PMID 34009843 Get It

Background: Endoscopic ultrasound–guided rendezvous (EUS-RV) endoscopic retrograde cholangiopancreatography (ERCP) is an alternative to interventional radiology–guided rendezvous ERCP in patients who failed biliary cannulation with conventional ERCP. However, there is significant variation in reported rates of success and adverse events associated with EUS-RV-assisted ERCP. We performed a systematic review and a proportion meta-analysis to reliably assess the effectiveness and safety of the EUS-RV-assisted ERCP. Materials and Methods: We conducted a comprehensive search of multiple electronic databases and conference proceedings (from inception through August 2020) to identify studies reporting EUS-RV-assisted ERCP in patients who failed biliary cannulation with conventional ERCP techniques. Using the random-effects model described by DerSimonian and Laird, we calculated the pooled rates of technical success, clinical success, and adverse events of EUS-RV-assisted ERCP. Results: Twelve studies reporting a total of 342 patients were included in the meta-analysis. The pooled rate of technical success (12 studies reporting a total of 342 patients) was 86.1% [95% confidence interval (CI): 78.4-91.3]. The pooled rate of clinical success (4 studies reporting a total of 94 patients) was 80.8% (95% CI: 64.1-90.8). The pooled rate of overall adverse events (12 studies; 42 events in 342 patients) was 14% (95% CI: 10.5-18.4). Low to moderate heterogeneity was noted in the analyses. Conclusions: EUS-RV-assisted ERCP appears to be effective and safe in patients who failed biliary cannulation with conventional ERCP. Given the risk of adverse events, it should be performed in centers with expertise in therapeutic endoscopic ultrasound.
ERCP with overtube-assisted enteroscopy in patients with Roux-en-Y gastric bypass anatomy: a systematic review and meta-analysis
Klair, Jagpal S. , Jayaraj, Mahendran , Chandrasekar, Viveksandeep Thoguluva , Priyan, Harshith, Law, Joanna K. , Murali, Arvind R. , Singh, Dhruv P. , Larsen, Michael , Irani, Shayan , Kozarek, Richard A. , Ross, Andrew S., Krishnamoorthi, Rajesh , Singh, Dhruv

Mayo Clinic

Endoscopy | June 3, 2020 | Volume: 52 | Issue: 10 | Pages: 824-832

10.1055/a-1178-9741 | PMID 32492751 Get It

AbstractBackground Endoscopic retrograde cholangiopancreatography (ERCP) in patients with Roux-en-Y gastric bypass (RYGB) anatomy is challenging. Overtube-assisted enteroscopy (OAE) is usually needed to perform ERCP in these patients. There is significant variation in the reported rates of success and adverse events across published studies. We performed a systematic review and meta-analysis to reliably estimate the pooled rates of success and adverse events.Methods We performed a systematic search of multiple electronic databases through February 2020 to identify studies reporting outcomes of OAE-ERCP in post-RYGB patients. The pooled rates of enteroscopy success, technical success, and adverse events were estimated for OAE-ERCP. The pooled rates of success and adverse events were also estimated for ERCP using double-balloon enteroscopes (DBE) alone.Results 10 studies reporting a total of 398 procedures were included in the meta-analysis. The pooled rates of enteroscopy and technical success of OAE-ERCP were 75.3 % (95 % confidence interval [CI] 64.5 – 83.6) and 64.8 % (95 %CI 53.1 – 74.9) respectively. The pooled rate of adverse events was 8.0 % (95 %CI 5.2 – 12.2). The pooled rates of enteroscopy and technical success of DBE-ERCP (four studies) were 83.5 % (95 %CI 68.3 – 92.2) and 72.5 % (95 %CI 52.3 – 86.4), respectively. The pooled rate of adverse events with DBE-ERCP was 9.0 % (95 %CI 5.4 – 14.5). Substantial heterogeneity was noted.Conclusions OAE-ERCP appears to be effective and safe in post-RYGB patients. Among the currently available techniques, OAE-ERCP is the least invasive approach in this challenging group of patients. Future studies comparing the effectiveness and safety of alternative novel techniques, such as endosonography-directed transgastric ERCP, with OAE-ERCP are needed.